all 13 news articles
If approved, Indiplon would enter a sleeping pill industry that is already dominated by Sanofi-Aventis' (Charts) Ambien CR, Sepracor's (Charts) Lunesta, ...
If approved, Indiplon would enter a sleeping pill industry that is already dominated by Sanofi-Aventis' (Charts) Ambien CR, Sepracor's (Charts) Lunesta, ...
Indiplon would compete with Sepracor's (SEPR - Cramer's Take - Stockpickr) Lunesta and Sanofi-Aventis' (SNY - Cramer's Take - Stockpickr) Ambien CR, ...
A couple in a commercial for Ambien CR, meanwhile, lie absolutely motionless all night until the darkness around them fades to daylight. ...
Ambien CR(TM) is showing strong resistance to the presence of Ambien(R) IR generics, with third-quarter net sales reaching $176 million in the United States ...
The company specified that the AMBIEN CR treated patients showed improvements in output and time management over a period of 12 weeks compared with patients ...
Unrestricted coverage of LUNESTA under managed care also grew to 85% of managed care lives compared to 77% for AMBIEN CR ® . ...
The company specified that the AMBIEN CR treated patients showed improvements in output and time management over a period of 12 weeks compared with patients ...
Honestly, vanity won out -- for a few days, I was wondering why I looked like those depressed people in an Ambien CR commercial when looking into the mirror ...